ALN-5288 vs Diranersen

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Alzheimer's Disease

Shared mechanism: MAPT mRNA (RNAi/ASO) · full Alzheimer's Disease pipeline

ALN-5288

Developed by Alnylam Pharmaceuticals and partners

Phase 1 in Alzheimer's DiseaseOligonucleotide (siRNA)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: March 2030 · NCT07214727 (registry estimate)

No aligned efficacy figure on record for this race.

Diranersen

Developed by Ionis Pharmaceuticals and partners

Phase 2 in Alzheimer's DiseaseOligonucleotide (ASO)
Weak signal

NCT03186989 · Phase 1 · completed

This dose-escalation study randomized participants to diranersen or placebo with both participants and staff blinded, but its primary endpoint was safety and tolerability rather than a cognitive or clinical outcome, which limits what it can show about therapeutic effect. Its registered primary outcome on ClinicalTrials.gov is "Part 1: Number of Participants With Adverse Events That Are Related to Treatment With ISIS 814907" (with 1 other safety or dose-finding measure). Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Reported efficacy

Dose response in Change From Baseline to Week 76 on the CDR-SB: Diranersen/BIIB080 (NCT05399888), Phase 2 CELIA study: primary endpoint (dose-response on CDR-SB change from baseline at Week 76) not met. (missed)

Result source: NCT05399888

Results for Alzheimer's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointALN-5288Diranersen
CDR-SB, change—Not reported—Not reported
ADAS-Cog11, change—Not reported—Not reported
ADCS-ADL, change—Not reported—Not reported
MMSE, change—Not reported—Not reported
Amyloid PET, change (centiloids)—Not reported—Not reported

CDR-SB, change

ALN-5288
—Not reported
Diranersen
—Not reported

ADAS-Cog11, change

ALN-5288
—Not reported
Diranersen
—Not reported

ADCS-ADL, change

ALN-5288
—Not reported
Diranersen
—Not reported

MMSE, change

ALN-5288
—Not reported
Diranersen
—Not reported

Amyloid PET, change (centiloids)

ALN-5288
—Not reported
Diranersen
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

ALN-5288: no structured comparison results are available for Alzheimer's Disease.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Diranersen
Diranersen/BIIB080 (NCT05399888), Phase 2 CELIA study: primary endpoint (dose-response on CDR-SB change from baseline at Week 76) not met. NCT05399888 · Phase 2 · design grade: moderate · publication or press release

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. ALN-5288: 0 of 4 rows · Diranersen: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricDiranersen
Dropout rate
7.7%115 mga
NCT03186989 · Phase 1 · monotherapy
show 9 more results
—115 mg
NCT03186989 · Phase 1 · combination
—115 mg
NCT03186989 · Phase 1 · combination
11.1%60 mg
NCT03186989 · Phase 1 · monotherapy
—60 mg
NCT03186989 · Phase 1 · combination
—60 mg
NCT03186989 · Phase 1 · combination
—60 mg
NCT03186989 · Phase 1 · combination
—60 mg
NCT03186989 · Phase 1 · combination
0%30 mg
NCT03186989 · Phase 1 · monotherapy
0%10 mg
NCT03186989 · Phase 1 · monotherapy
Discontinued due to AEs
—115 mga
NCT03186989 · Phase 1 · monotherapy
show 9 more results
—115 mg
NCT03186989 · Phase 1 · combination
—115 mg
NCT03186989 · Phase 1 · combination
—60 mg
NCT03186989 · Phase 1 · monotherapy
—60 mg
NCT03186989 · Phase 1 · combination
—60 mg
NCT03186989 · Phase 1 · combination
—60 mg
NCT03186989 · Phase 1 · combination
—60 mg
NCT03186989 · Phase 1 · combination
—30 mg
NCT03186989 · Phase 1 · monotherapy
—10 mg
NCT03186989 · Phase 1 · monotherapy
Serious AEs
0%115 mga
NCT03186989 · Phase 1 · monotherapy
show 9 more results
10%115 mg
NCT03186989 · Phase 1 · combination
0%115 mg
NCT03186989 · Phase 1 · combination
0%60 mg
NCT03186989 · Phase 1 · monotherapy
33.3%60 mg
NCT03186989 · Phase 1 · combination
20%60 mg
NCT03186989 · Phase 1 · combination
0%60 mg
NCT03186989 · Phase 1 · combination
25%60 mg
NCT03186989 · Phase 1 · combination
0%30 mg
NCT03186989 · Phase 1 · monotherapy
0%10 mg
NCT03186989 · Phase 1 · monotherapy
Most frequent reported AEs
115 mga
confusional state 23.1% (placebo 0%)
post lumbar puncture syndrome 23.1% (placebo 25%)
headache 15.4% (placebo 25%)
NCT03186989 · Phase 1 · monotherapy
show 9 more results
115 mg
back pain 50% (placebo 8.3%)
headache 40% (placebo 25%)
fatigue 30% (placebo 0%)
NCT03186989 · Phase 1 · combination
115 mg
back pain 75% (placebo 8.3%)
confusional state 25% (placebo 0%)
dementia alzheimer's type 25% (placebo 0%)
NCT03186989 · Phase 1 · combination
60 mg
headache 33.3% (placebo 25%)
procedural pain 33.3% (placebo 8.3%)
back pain 22.2% (placebo 8.3%)
NCT03186989 · Phase 1 · monotherapy
60 mg
agitation 33.3% (placebo 0%)
anxiety 33.3% (placebo 0%)
back pain 33.3% (placebo 8.3%)
NCT03186989 · Phase 1 · combination
60 mg
back pain 40% (placebo 8.3%)
albumin csf increased 20% (placebo 0%)
chronic obstructive pulmonary disease 20% (placebo 0%)
NCT03186989 · Phase 1 · combination
60 mg
dizziness 42.9% (placebo 8.3%)
procedural pain 42.9% (placebo 8.3%)
pain in extremity 28.6% (placebo 0%)
NCT03186989 · Phase 1 · combination
60 mg
pain in extremity 50% (placebo 0%)
aggression 25% (placebo 0%)
agitation 25% (placebo 0%)
NCT03186989 · Phase 1 · combination
30 mg
headache 50% (placebo 25%)
diarrhoea 33.3% (placebo 0%)
nausea 33.3% (placebo 0%)
NCT03186989 · Phase 1 · monotherapy
10 mg
post lumbar puncture syndrome 50% (placebo 25%)
headache 33.3% (placebo 25%)
procedural pain 33.3% (placebo 8.3%)
NCT03186989 · Phase 1 · monotherapy

Notes

  1. aPopulation comparability has not been reviewed for these studies.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ALN-5288's landscape · Diranersen's landscape